Zenotech Lab.

Why is Zenotech Laboratories Ltd falling/rising?

As of 20-Jun, Zenotech Laboratories Ltd's stock price is declining, currently at Rs 44.35, down 4.83%. The stock has underperformed the sector, showing a year-to-date decline of 3.98% and a significant drop of 27.53% over the past year.

As of 20-Jun, Zenotech Laboratories Ltd's stock price is falling, currently at Rs 44.35, which reflects a decrease of Rs 2.25 or 4.83%. The stock has been underperforming compared to the sector, with a performance today that is down by 5.55%. Additionally, it has experienced consecutive declines over the last two days, resulting in a total drop of 5.09% during this period.<BR><BR>The stock's volatility is notable, with an intraday volatility of 6.74%, and it has traded within a wide range of Rs 6.06 today, reaching a high of Rs 48 and a low of Rs 41.94. Furthermore, Zenotech Laboratories Ltd is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 137.79% against the 5-day average, the overall performance metrics indicate a struggling stock. Year-to-date, the stock has declined by 3.98%, and over the past year, it has fallen by 27.53%, contrasting sharply with the Sensex, which has only decreased by 5.60% in the same timeframe. These factors collectively contribute to the current downward movement of Zenotech Laboratories Ltd's stock price.

Which are the latest news on Zenotech Lab.?

Should I buy, sell or hold Zenotech Laboratories Ltd?

Who are in the management team of Zenotech Lab.?

The management team of Zenotech Lab includes Kavita Shah, Jignesh Anantray Goradia, Azadar Hussain Khan, Chintan Jitendra Shah, Abdul Gafoor Mohammad, Jagruti Prashant Sheth, and Rakeshchandra Jagdishprasad Sinha, serving in various roles such as Independent and Non-Executive Directors, and Company Secretary.

The management team of Zenotech Lab includes the following individuals:<BR><BR>1. Kavita Shah - Independent Director<BR>2. Jignesh Anantray Goradia - Non Executive Director<BR>3. Azadar Hussain Khan - Non Executive Director<BR>4. Chintan Jitendra Shah - Independent Director<BR>5. Abdul Gafoor Mohammad - Company Secretary & Compliance Officer<BR>6. Jagruti Prashant Sheth - Independent Director<BR>7. Rakeshchandra Jagdishprasad Sinha - Non Executive Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Zenotech Lab.?

Zenotech Lab.'s peers include Medico Remedies, Transchem, Medicamen Biotec, Trident Lifeline, Lyka Labs, Astonea Labs, Gennex Lab., Ambalal Sarabhai, and Infinium Pharma. Key insights show varying management risks, growth rates, and capital structures among these companies, with Transchem leading in 1-year returns at 605.82% and Medicamen Biotec lagging at -46.53%.

Peers: The peers of Zenotech Lab. are Medico Remedies, Transchem, Medicamen Biotec, Trident Lifeline, Lyka Labs, Astonea Labs, Gennex Lab., Ambalal Sarabhai, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medicamen Biotec and Trident Lifeline, while Average management risk is found at Transchem, Lyka Labs, Astonea Labs, Gennex Lab., and the rest. Growth is Excellent at Trident Lifeline, Good at Zenotech Lab., Astonea Labs, and Gennex Lab., while Below Average growth is noted at Medico Remedies, Transchem, Medicamen Biotec, Lyka Labs, and the rest. Capital Structure is Excellent at Medicamen Biotec, Zenotech Lab., Gennex Lab., and Infinium Pharma, Good at Medico Remedies and Trident Lifeline, while Below Average is seen at Lyka Labs, Astonea Labs, Ambalal Sarabhai, and the rest.<BR><BR>Return Snapshot: Transchem has the highest 1-year return at 605.82%, while Medicamen Biotec has the lowest at -46.53%. Zenotech Lab.'s own 1-year return is -29.86%, which is better than Medicamen Biotec but worse than Transchem. Additionally, the six-month return is negative for Medico Remedies, Medicamen Biotec, Trident Lifeline, Gennex Lab., and Infinium Pharma.

What does Zenotech Lab. do?

Zenotech Laboratories Ltd is a micro-cap pharmaceutical company specializing in generic injectables, established in 1989. As of March 2026, it reported net sales of 9 Cr and a net loss of 3 Cr, with a market cap of INR 277 Cr.

Overview: <BR>Zenotech Laboratories Ltd is a pharmaceutical specialty generic injectables company operating in the Pharmaceuticals & Biotechnology industry within the micro-cap market segment.<BR><BR>History: <BR>Zenotech Laboratories Ltd was established in June 1989 and changed its name from Sunline Technologies Limited to its current name on August 9, 2004. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -3 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 277 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.32 <BR>Return on Equity: -1.00% <BR>Price to Book: 2.86 <BR><BR>Contact Details: <BR>Address: S No 250-252 Turkapally Village, Shameerpet Mandal RR District Hyderabad Telangana: 500078 <BR>Tel: 91-40-23480430/0435 <BR>Email: abdul.gafoor@zenotech.co.in <BR>Website: http://www.zenotechlab.com

Are Zenotech Laboratories Ltd latest results good or bad?

Zenotech Laboratories Ltd's latest Q4 FY26 results are concerning, showing a net profit of ₹-3.15 crores and a 25.02% decline in revenue. The significant drop in operating and profit margins indicates serious operational challenges, suggesting a negative outlook for the company.

Zenotech Laboratories Ltd's latest results for Q4 FY26 are concerning and indicate a significant deterioration in financial performance. The company reported a net profit of ₹-3.15 crores, which reflects a staggering decline of 263.21% compared to the previous quarter. Revenue also fell sharply to ₹8.87 crores, down 25.02% quarter-on-quarter and 20.16% year-on-year.<BR><BR>The operating margin has collapsed to just 2.03%, the lowest in seven quarters, signaling severe operational challenges. Additionally, the profit after tax (PAT) margin turned negative at -35.51%, a drastic drop from the previous quarter's positive margin of 16.31%. <BR><BR>Overall, these results suggest that Zenotech is facing significant operational inefficiencies and market challenges, making the latest performance decidedly negative. Investors should approach the stock with caution given the current trajectory of its financial health.

When is the next results date for Zenotech Laboratories Ltd?

The next results date for Zenotech Laboratories Ltd is April 29, 2026.

The next results date for Zenotech Laboratories Ltd is scheduled for April 29, 2026.

How has been the historical performance of Zenotech Lab.?

Zenotech Lab has experienced declining net sales and increasing losses from 2008 to 2010, with net sales dropping from 8.24 Cr to 6.57 Cr. However, there are signs of improvement in cash management, as cash and cash equivalents rose significantly during the same period.

Answer:<BR>The historical performance of Zenotech Lab shows a trend of declining net sales and increasing losses over the years reported.<BR><BR>Breakdown:<BR>Zenotech Lab's net sales decreased from 8.24 Cr in March 2008 to 6.57 Cr in March 2010, with a slight increase from 6.02 Cr in March 2009. The total operating income mirrored this trend, remaining at 6.57 Cr in March 2010, down from 8.24 Cr in March 2008. The total expenditure, excluding depreciation, also declined from 18.12 Cr in March 2008 to 16.01 Cr in March 2010. However, the operating profit (PBDIT) remained negative, improving slightly from -9.88 Cr in March 2008 to -7.33 Cr in March 2010. The profit before tax showed a similar pattern, with losses narrowing from -13.54 Cr in March 2008 to -12.54 Cr in March 2010. The profit after tax also reflected this negative trend, with losses of -15.89 Cr in March 2008, -17.56 Cr in March 2009, and -12.53 Cr in March 2010. The earnings per share improved from -4.39 in March 2008 to -3.45 in March 2010. Cash flow from operating activities remained negative, although it improved from -15.54 Cr in March 2009 to -9.85 Cr in March 2010. The closing cash and cash equivalents increased significantly from 0.60 Cr in March 2008 to 12.33 Cr in March 2010, indicating a positive cash flow from investing activities. Overall, Zenotech Lab has faced challenges with profitability, but there are signs of improvement in cash management.

How big is Zenotech Lab.?

As of 24th July, Zenotech Laboratories Ltd has a market capitalization of 391.00 Cr and reported net sales of 38.97 Cr and a net profit of 5.56 Cr in the latest four quarters. Specific values for Shareholder's Funds and Total Assets are not available.

As of 24th July, Zenotech Laboratories Ltd has a market capitalization of 391.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, Zenotech Laboratories Ltd reported net sales of 38.97 Cr and a net profit of 5.56 Cr.<BR><BR>The reporting period for the balance sheet is the latest annual period, but specific values for Shareholder's Funds and Total Assets are not available.

Who are the top shareholders of the Zenotech Lab.?

The top shareholders of Zenotech Lab are Sun Pharmaceutical Industries Limited with 68.84%, followed by Padmasree Chigurupati at 5.26%, and individual investors holding 22.78%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Zenotech Lab include Sun Pharmaceutical Industries Limited, which holds a significant majority stake of 68.84%. The highest public shareholder is Padmasree Chigurupati, with a holding of 5.26%. Additionally, individual investors collectively hold 22.78% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Zenotech Lab.

Is Zenotech Lab. overvalued or undervalued?

Zenotech Lab. is currently considered very expensive and overvalued due to high valuation metrics and poor stock performance, making it a less compelling investment at its current price.

As of 13 August 2021, the valuation grade for Zenotech Lab. has moved from risky to very expensive. The company is currently overvalued based on its high valuation metrics, including a PE ratio of 86.06, an EV to EBIT ratio of 49.55, and an EV to EBITDA ratio of 25.21. These figures significantly exceed those of its peers, such as Sun Pharma with a PE of 35.25 and Divi's Lab at 79.33, indicating that Zenotech Lab. is trading at a premium compared to the industry.<BR><BR>In comparison to the broader market, Zenotech Lab.'s stock has underperformed year-to-date with a return of -11.95% against the Sensex's 5.63%. This trend reinforces the conclusion that the stock is overvalued, as investors may be paying a high price for earnings that do not justify such a valuation. Overall, the combination of elevated ratios and poor relative performance suggests that Zenotech Lab. is not a compelling investment at its current price.

What is the technical trend for Zenotech Lab.?

As of May 12, 2025, Zenotech Lab's technical trend is mildly bearish, with mixed signals from MACD, Bollinger Bands, and moving averages across different time frames.

As of 12 May 2025, the technical trend for Zenotech Lab has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The Bollinger Bands show a mildly bullish trend on the weekly chart but are bearish on the monthly, further contributing to the overall mildly bearish outlook. Daily moving averages are also mildly bearish, reinforcing the current trend. The KST is mildly bullish on the weekly but mildly bearish on the monthly, indicating some short-term strength that is not reflected in the longer term. Overall, the current technical stance is mildly bearish, with key indicators showing mixed signals across different time frames.

Has Zenotech Lab. declared dividend?

No Dividend History Available